Sanofi C-suite explains Regeneron deal 'simplification,' ramping up its pipeline

It’s been a busy year for Sanofi: It’s been rejigging deals with the likes of Regeneron and bought out a biotech in the form of Synthorx.

In its fourth-quarter/full-year update Thursday, analysts, as ever, had more M&A on their minds. Sanofi spent $2.5 billion on that Synthorx deal late last year, nabbing an IL-2 drug the pharma thinks can become a foundation of immuno-oncology combinations. In the future, more deals may take a similar shape.